Nature Communications (Apr 2023)

Associate toxin-antitoxin with CRISPR-Cas to kill multidrug-resistant pathogens

  • Rui Wang,
  • Xian Shu,
  • Huiwei Zhao,
  • Qiong Xue,
  • Chao Liu,
  • Aici Wu,
  • Feiyue Cheng,
  • Lingyun Wang,
  • Yihan Zhang,
  • Jie Feng,
  • Nannan Wu,
  • Ming Li

DOI
https://doi.org/10.1038/s41467-023-37789-y
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 13

Abstract

Read online

Abstract CreTA, CRISPR-regulated toxin-antitoxin (TA), safeguards CRISPR-Cas immune systems by inducing cell dormancy/death upon their inactivation. Here, we characterize a bacterial CreTA associating with the I-F CRISPR-Cas in Acinetobacter. CreT is a distinct bactericidal small RNA likely targeting several essential RNA molecules that are required to initiate protein synthesis. CreA guides the CRISPR effector to transcriptionally repress CreT. We further demonstrate a proof-of-concept antimicrobial strategy named ATTACK, which AssociaTes TA and CRISPR-Cas to Kill multidrug resistant (MDR) pathogens. In this design, CRISPR-Cas is programed to target antibiotic resistance gene(s) to selectively kill MDR pathogens or cure their resistance, and when CRISPR-Cas is inactivated or suppressed by unwanted genetic or non-genetic events/factors, CreTA triggers cell death as the last resort. Our data highlight the diversity of RNA toxins coevolving with CRISPR-Cas, and illuminate a combined strategy of CRISPR and TA antimicrobials to ‘ATTACK’ MDR pathogens.